Samuel Funt

26PUBLICATIONS
183CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methodsCancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 14, 2026
The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.

|Feb 02, 2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran

|Nov 04, 2025
Validation of the Testicular Health Outcomes Report (THOR): a testicular cancer health-related quality of life instrument.

Samuel A Gold, Amy L Tin, Viranda H Jayalath

|Jun 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research.

Michal Sternschuss, Michael Lattanzi, Emily Vertosick

|Jul 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease.

Jack P Gleeson, Andrea Knezevic, Maria Bromberg

|May 01, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.

Andrew T Lenis, Karissa Whiting, Vignesh Ravichandran

Pageof 5

Frequent Collaborators

14 joint publications

Hikmat Al-Ahmadie

10 joint publications

Dean F Bajorin

10 joint publications

Jonathan E Rosenberg

10 joint publications

Gopa Iyer